China’s Supreme Court Upholds Semaglutide Patent for Novo Nordisk
China’s Supreme People’s Court upholds Novo Nordisk’s semaglutide compound patent, supporting IP protection.
Over 600,000 Californians Risk Losing Access to GLP-1 Weight-Loss Drugs
California’s Medi-Cal will stop covering GLP-1 weight-loss drugs for weight-loss-only prescriptions, effective Jan. 1, 2026.
Weight-Loss Pill Approval Likely to Prompt Overhaul of Packaged Food and Fast-Food Products
FDA approval of GLP-1 weight-loss pills may prompt food makers and restaurants to shift to high-protein, smaller-portion products.
FDA Approves New Oral Wegovy Pill for 2026, Revolutionizing Semaglutide Administration
Analysis of 2026 semaglutide options: FDA-approved oral Wegovy, injectables, compounded pathways, costs and safety.
How to Taper Off GLP-1 Medications Safely
How to gradually taper GLP-1 meds to curb hunger, prevent rapid weight regain, and stabilize blood sugar with medical guidance, lifestyle changes, and close monitoring.
5 Tools for Tracking GLP-1 Progress
Compare five tools—patient portal, three apps, and printable journals—for logging GLP‑1 injections, weight, injection sites, and side effects to optimize treatment.
How to Prevent Bruising After GLP-1 Injections
Practical tips to reduce bruising after GLP-1 injections: proper site rotation, 90° technique, fresh needles, warm medication, and post-injection pressure.
Tirzepatide Contraindications: Who Should Avoid It?
Who shouldn’t use tirzepatide? Review contraindications, caution conditions, and safer alternatives for diabetes and weight-loss care.
Zepbound Dosing for Weight Loss Beginners
Step-by-step Zepbound dosing for beginners: start at 2.5 mg weekly, titrate to 15 mg, manage side effects, track progress, and pair with diet and strength training.
